WO2002102974A3 - Mutant proteins, high potency inhibitory antibodies and fimch crystal structure - Google Patents

Mutant proteins, high potency inhibitory antibodies and fimch crystal structure Download PDF

Info

Publication number
WO2002102974A3
WO2002102974A3 PCT/US2001/047994 US0147994W WO02102974A3 WO 2002102974 A3 WO2002102974 A3 WO 2002102974A3 US 0147994 W US0147994 W US 0147994W WO 02102974 A3 WO02102974 A3 WO 02102974A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
fimch
crystal structure
provides
antibodies
Prior art date
Application number
PCT/US2001/047994
Other languages
French (fr)
Other versions
WO2002102974A2 (en
Inventor
Solomon R Langermann
Scott J Hultgren
Chia-Suei Hung
Julie Bouckaert
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Priority to AU2001297896A priority Critical patent/AU2001297896A1/en
Publication of WO2002102974A2 publication Critical patent/WO2002102974A2/en
Publication of WO2002102974A3 publication Critical patent/WO2002102974A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Abstract

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response, It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or treat pathogenic bacterial infections. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of FimCH bound to mannose, and subsets thereof, and methods of using the crystal structure to provide candidate amino acid residues for mutation.
PCT/US2001/047994 2000-12-08 2001-12-10 Mutant proteins, high potency inhibitory antibodies and fimch crystal structure WO2002102974A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001297896A AU2001297896A1 (en) 2000-12-08 2001-12-10 Mutant proteins, high potency inhibitory antibodies and fimch crystal structure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25435300P 2000-12-08 2000-12-08
US60/254,353 2000-12-08
US30187801P 2001-06-29 2001-06-29
US60/301,878 2001-06-29

Publications (2)

Publication Number Publication Date
WO2002102974A2 WO2002102974A2 (en) 2002-12-27
WO2002102974A3 true WO2002102974A3 (en) 2003-05-22

Family

ID=26944001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047994 WO2002102974A2 (en) 2000-12-08 2001-12-10 Mutant proteins, high potency inhibitory antibodies and fimch crystal structure

Country Status (3)

Country Link
US (1) US20030199071A1 (en)
AU (1) AU2001297896A1 (en)
WO (1) WO2002102974A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
JP4557714B2 (en) * 2002-05-10 2010-10-06 メディミューン，エルエルシー EphA2 monoclonal antibody and method of use thereof
WO2004003160A2 (en) * 2002-06-27 2004-01-08 University Of Washington Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
CA2823937A1 (en) * 2002-10-07 2004-04-22 Novartis Vaccines And Diagnostics, Inc. Hiv vaccine formulations
EP1610757A4 (en) * 2003-04-10 2007-05-30 Transform Pharmaceuticals Inc Profiling conformational variants, antibody compositions and methods of using the same
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
KR101224235B1 (en) 2003-04-11 2013-01-25 메디뮨 엘엘씨 Recombinant IL-9 Antibodies and Uses Thereof
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
US20090215627A1 (en) * 2004-08-06 2009-08-27 Yang Shen Crystal Structure of Biotin Carboxylase (Bc) Domain of Acetyl-Coenzyme a Carboxylase and Methods of Use Thereof
US9079945B2 (en) * 2005-01-11 2015-07-14 Naval Medical Research Center Adhesin as immunogen against enterotoxigenic Escherichia coli
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2010040073A1 (en) * 2008-10-03 2010-04-08 Xoma Technology Ltd. Novel triple tag sequences and methods of use thereof
EP2920203B1 (en) 2012-11-19 2019-06-05 The United States of America as represented by the Secretary of the Navy Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits
WO2014145906A2 (en) * 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
JP2017537145A (en) 2014-11-05 2017-12-14 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ Synthetic antigen construct against Campylobacter jejuni
WO2016149417A1 (en) * 2015-03-17 2016-09-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3069729A1 (en) * 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10722580B2 (en) * 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
BR112022013720A2 (en) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc MUTANT FIMH, COMPOSITIONS WITH IT AND ITS USE
EP4277921A1 (en) 2021-01-12 2023-11-22 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971794A (en) * 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
US4882425A (en) * 1987-07-09 1989-11-21 Baylor College Of Medicine Receptor specific proteins and their use in receptor typing

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABRAHAM S.N. ET AL.: "Protection against escherichia coli-induced urinary tract infections with hybridoma antibodies directed against type 1 fimbriae or complementary D-mannose receptors", INFECTION AND IMMUNITY, vol. 48, no. 3, June 1985 (1985-06-01), pages 625 - 628, XP002961101 *
LANGERMANN S. ET AL.: "Prevention of mucosal escherichia coli infection by FimH-adhesin-based systemic vaccination", SCIENCE, vol. 276, 25 April 1997 (1997-04-25), pages 607 - 611, XP002944646 *
LANGERMANN S. ET AL.: "Vaccination utilizing the FimCH complex as a strategy to prevent escherichia coli urinary tract infections", THE JOURNAL OF INFECTIOUS DISEASES, vol. 183, no. SUPPL. 1, 2001, pages S84 - S86, XP001053569 *
LANGERMANN S. ET AL.: "Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic escherichia coli", THE JOURNAL OF INFECTIOUS DISEASES, vol. 181, 2000, pages 774 - 778, XP002944650 *
SCHEMBRI M.A. ET AL.: "Molecular characterization of the escherichia coli FimH adhesin", THE JOURNAL OF INFECTIOUS DISEASES, vol. 183, no. SUPPL. 1, 2001, pages S28 - S31, XP002961102 *
SCHILLING J.D. ET AL.: "Structure and function of escherichia coli type 1 Pili: New insight into the pathogenesis of urinary tract infections", THE JOURNAL OF INFECTIOUS DISEASES, vol. 183, no. SUPPL. 1, 2001, pages S36 - S40, XP002961103 *
UEHLING D.T.: "Vaginal mucosal immunization for recurrent urinary tract infection: Extended phase II clinical trial", THE JOURNAL OF INFECTIOUS DISEASES, vol. 183, no. SUPPL. 1, 2001, pages S81 - S83, XP002961104 *
WIZEMANN T.M. ET AL.: "Adhesins as targets for vaccine development", EMERGING INFECTIOUS DISEASES, vol. 5, no. 3, May 1999 (1999-05-01) - June 1999 (1999-06-01), pages 395 - 403, XP002938711 *

Also Published As

Publication number Publication date
AU2001297896A1 (en) 2003-01-02
US20030199071A1 (en) 2003-10-23
WO2002102974A2 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
WO2002102974A3 (en) Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
ATE461709T1 (en) CHOLINE-BINDING PROTEINS DERIVATIVES FROM PNEUMOCOCES AS VACCINES
DK0950068T3 (en) Collagen-binding protein compositions and methods of use
DE60323090D1 (en) 1H-IMIDAZOÄ4,5-CÜCHINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES
NZ583028A (en) Nucleic acids and proteins from streptococcus groups A & B
EA200201280A1 (en) Streptokokovye antigens
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
IN2015KN00290A (en)
NO960309L (en) Agonists and antagonists of human interleukin-10
EP4226938A3 (en) Coronavirus vaccine
CN108135992A (en) Immunogenic fusion proteins
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2023147092A3 (en) Coronavirus vaccine
WO2005007673A3 (en) Immunogenic peptides
Piccioli et al. GMMA as a ‘plug and play’technology to tackle infectious disease to improve global health: Context and perspectives for the future
Sriprapat et al. The impact of a low dose, low volume, multi-site immunization on the production of therapeutic antivenoms in Thailand
DE69833876D1 (en) COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF BIOLOGICAL ACTIVE FACTORS
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
US20110020356A1 (en) Therapeutic clostridium difficile antibody compositions
Dunkley et al. Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein
DE69924877D1 (en) Humanes akt-3 protein
NZ515330A (en) Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
DE60227367D1 (en) MODIFIED GRANULOCYTE STIMULATING FACTOR (G-CSF) WITH REDUCED IMMUNOGENITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP